View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 19, 2022

Sorrento secures Brazil clearance to start Phase IIa long Covid trial

The trial will assess the safety and efficacy of up to three intravenous doses of COVI-MSC administered on alternate days.

Sorrento Therapeutics has secured the Brazilian health regulatory agency ANVISA authorisation to commence a Phase IIa clinical trial of COVI-MSC for treating ‘long haul’ pulmonary compromise following Covid-19 infection, or long Covid.

COVI-MSC is a human allogeneic adipose-derived mesenchymal stromal cells (MSC) product candidate.

The multicentre, randomised, placebo-controlled trial will analyse the safety and efficacy of up to three intravenous doses of COVI-MSC given on alternate days versus placebo, along with standard of care.

It will have 60 individuals who have been experiencing respiratory issues as a result of a SARS-CoV-2 infection a minimum of three months before enrolment into the trial.

Improvement in the six-Minute Walk Distance (6MWD) test at day 60 following treatment, will be the primary outcome measure of the trial.

Sorrento anticipates this enrolment pace due to the previous broad Covid-19 burden in Brazil; its collaboration with domestic clinical research organisation Synova Health; and present associations with quality medical centres in the country. 

The alliance with Synova Health makes use of quality study centres as well as a dozen centres that have previously taken part in other acute Covid-19 trials of Abivertinib and MSC with Sorrento.

Sorrento Therapeutics chairman and CEO Dr Henry Ji said: “We are very satisfied with the progress made in Brazil so far, and we have developed very strong local relationships in support of multiple studies. 

“We expect this next Phase II study to confirm the clinical benefits for long-hauler patients. Long-hauler syndrome is likely to be the next major challenge for medical systems in a post-Covid era, and we intend to be the leaders in addressing this future unmet need.”

In July last year, the company dosed participants in a Phase II trial of its intranasal drug, COVIDROPS, to treat Covid-19 in the outpatient setting in the UK.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy